Abstract
Components of circadian rhythm maintenance, or “clock genes,” are endogenous entrainable oscillations of about 24 h that regulate biological processes and are found in the suprachaismatic nucleus (SCN) and many peripheral tissues, including the heart. They are influenced by external cues, or Zeitgebers, such as light and heat, and can influence such diverse phenomena as cytokine expression immune cells, metabolic activity of cardiac myocytes, and vasodilator regulation by vascular endothelial cells. While it is known that the central master clock in the SCN synchronizes peripheral physiologic rhythms, the mechanisms by which the information is transmitted are complex and may include hormonal, metabolic, and neuronal inputs. Whether circadian patterns are causally related to the observed periodicity of events, or whether they are simply epi-phenomena is not well established, but a few studies suggest that the circadian effects likely are real in their impact on myocardial infarct incidence. Cycle disturbances may be harbingers of predisposition and subsequent response to acute and chronic cardiac injury, and identifying the complex interactions of circadian rhythms and myocardial infarction may provide insights into possible preventative and therapeutic strategies for susceptible populations.
Clinical associations for circadian rhythms in myocardial infarction
The ability to properly synchronize with the external environment is an essential element of animal survival. The predation rate of free-living chipmunks increased over time in suprachiasmatic nucleus (SCN)-lesioned animals due to their reduced burrowing during the nighttime (Decoursey et al., 2000). On the other hand, rats kept in total darkness during the first 48 h following brain injury exhibited improved recovery (Corwin and Vargo, 1993; Vargo et al., 1998, 1999). In humans, disruptions in rhythms are associated with reduced survival of patients with metastatic cancers (Mormont et al., 2000; Sephton et al., 2000) and alterations in expression of clock genes have been shown to be responsible for unregulated cell growth (Granda et al., 2005; Chu et al., 2008; Clairambault, 2008; Yang et al., 2008).
The significance of circadian rhythms to myocardial infarction has been identified in several studies in which onset of non-Q-wave angina, unstable angina, myocardial infarctions, and sudden cardiac death all show marked elevations in occurrence between the hours of 0600 and 1200 (Muller, 1999a,b; Willich et al., 2004; Mosendane and Raal, 2008). Ethnic genetic, medications, co-morbidities, lifestyle, cultural, and/or social factors may shift the time of highest incidence (Kanth et al., 2013). Lopez et al. (2005) and Savopoulos et al. (2006) each reported a significant shift to the 1800–2400 h window for increased incidence of sudden death in Mediterranean populations. The incidence of ischemic stroke, has been reported to follow the same patterns (Gupta and Shetty, 2005), with highest incidence in the 0600–1200 window and diurnal variation in ventricular arrhythmias have recently been demonstrated to be related to abnormal repolarization (Jeyaraj et al., 2012). The time of day when an event occurs also may influence the severity of the outcome (Mukamal et al., 2000) and also may extend to the timing of salvaging intervention. The time of day when mechanical reperfusion by percutaneous transluminal coronary angioplasty (PTCA) is performed influences subsequent 1 year mortality rates, with patients treated between 0400 and 0800 having worse outcomes than all others, even after correcting for confounding variables (De Luca et al., 2005).
Blood pressure normally follows a diurnal pattern, with pressures lowest at night, and rising to a peak in the hours 0600–1000. Several ambulatory blood pressure studies have identified that failure to decrease blood pressure at night, so called “non-dipping,” is associated with increased cardiovascular risk (Morgan, 2002; Lee et al., 2005; Izzedine et al., 2006), and optimal efficacy in relation to time of day is a major factor considered in anti-hypertensive drug development (Lemmer, 2006). More recently, it has been shown that Per2 mutation diminishes blood pressure and heart rate dipping (Vukolic et al., 2010). Many intrinsic vasoactive and cardioactive substances, such as angiotensin II, melatonin, plasminogen activator inhibitor 1 (pai-1), glucocorticoids, epinephrine, norepinephrine, and nitric oxide follow distinct circadian patterns (Ding et al., 1994; Balsalobre et al., 2000; McNamara et al., 2001; Nonaka et al., 2001; Naito et al., 2003; Tsuchiya et al., 2005; Tsujino et al., 2005; Vaughan, 2005; Kanth et al., 2013). To the extent that diabetes and obesity are contributing factors to cardiovascular risk, recent reviews associating circadian genes with metabolic dysfunction in peripheral tissues are noteworthy. And whether these many circadian patterns are causally related to the observed periodicity of events, or whether they are simply epiphenomena is not well established, but a few studies suggest that the circadian effects likely are real in their impact on myocardial infarction incidence (Bray and Young, 2007; Green et al., 2008; Prasai et al., 2008; Ruger and Scheer, 2009; Durgan and Young, 2010; Maury et al., 2010; Bailey et al., 2014; Nedeltcheva and Scheer, 2014). Chronic instability in circadian rhythm in shift worker studies was recognized more than 20 years ago to produce increased risk of cardiovascular morbidity and mortality (Knutsson et al., 1986). More recently, Fujino et al. (2006) reported that the relative risk for ischemic heart disease in Japanese factory workers on rotating shifts doubles compared to that of workers with either fixed daytime or fixed night-time schedules. Kawachi et al. reported similar findings in a study of U.S. nurses, with the multivariate risk increasing commensurate with the duration of rotating shift work (Kawachi et al., 1995). Notably, in hamsters with a mutation producing a 22 h circadian cycle, premature cardiac mortality was noted, and corrected when either the animals were converted to a 22 h L/D cycle matching the phenotype, or the SCN was ablated, abolishing the dys-synchrony (Martino et al., 2008). Further, the same group also demonstrated that when mice were maintained in a disrupted light/dark (L/D) rhythm (10/10 vs. normal 12/12), the hypertrophy response to aortic banding was badly impaired (Martino et al., 2007).
These findings are consistent with the premise that synchronization between the central and peripheral clocks is a continuous, ongoing process, and that the pressure to maintain this synchronization involves signaling mechanisms that are energetically demanding for the peripheral target tissues. When coupled with an underlying pathophysiology that generates a vulnerable substrate, such as coronary artery disease or pressure overload, the pressure to normalize desynchronized rhythms increases the progression of injury.
Circadian rhythm biology
Circadian rhythms are daily variations of physiological functions that are found in every living organism. These daily rhythms are generated through the integration of oscillatory expression of multiple circadian clock genes (Harmer et al., 2001; Dvornyk et al., 2003; Merrow et al., 2005; Granados-Fuentes and Herzog, 2013). In mammals, the circadian rhythms are regulated by the SCN of the hypothalamus. Neurons in the SCN generate self-sustained daily oscillations of gene expression and electrical activity with a frequency of close to 24 h (Herzog and Schwartz, 2002). The SCN keeps the circadian rhythms of different peripheral organs synchronized to each other as well as to the environmental light-dark cycle (Dardente and Cermakian, 2005). Although every mammalian cell is believed to express the circadian clock genes, it has been shown that some cells outside the SCN are not able to maintain self-sustained circadian oscillation in the absence of the SCN (Fukuhara and Tosini, 2003).
Major progress has been made in identifying genes that regulate the circadian clock (Hardin and Glossop, 1999; Reppert and Weaver, 2002; Hardin, 2006; Hardin and Panda, 2013). The first circadian clock gene was identified in drosophila, named Period (per) (Kyriacou and Hall, 1980). The first mammalian counterpart of the Period gene was discovered by Sun et al. (1997). Molecular components of the circadian clock have been identified in mammals and interact to contribute to the entrainment and pace making of the circadian rhythm. These genes include a clock gene, a gene encoding brain-muscle Arnt-like protein 1 (bmal1) (Honma et al., 1998), three period genes (per1, per2, and per3) (Sun et al., 1997; Zheng et al., 1999; Shearman et al., 2000), and two cryptochrome genes (cry1 and cry2) (Thresher et al., 1998; Hardin and Glossop, 1999; Sancar, 2000). In addition, there is evidence that the NPAS2 gene, which encodes a functional analog of the clock, may play a role in the functioning of the circadian clock in the brain as well as peripheral organs (Reick et al., 2001; Hardin, 2006).
These clock genes participate in the pacemaking and phase regulation of the circadian rhythm. In the mammalian cells, CLOCK/BMAL1 form heterodimers that are positive regulators which activate the transcription of per1, per2, and per3 through a transcription factor binding site, located in the promoter region of the per genes. Per1, per2, and per3 mRNA are transcribed and move to the cytoplasm, where they are translated into PER1, PER2, and PER3 proteins. As the levels of PER1 and PER2 proteins increase and begin to form PER1/PER2 heterodimers, the protein complex enters the nuclei. However, nuclear translocation of the PER1/PER2 heterodimers is tightly regulated. Cryptochrome proteins, CRY1 and CRY2, negatively regulate clock feedback while PER3 enhances translocation of PER1 and PER2 to the nucleus (Sangoram et al., 1998; Glossop et al., 1999; Kume et al., 1999; Shearman et al., 2000; Yagita et al., 2000; Lee et al., 2001). Doubletime (or casein kinase Ie in mouse), can bind and phosphorylate PER1 and PER2, thereby masking PER1's nucleus localization signaling, promoting its retention in the cytoplasm and thereby its degradation (Glossop et al., 1999; Xu et al., 2007). In addition, CRY1/CRY2 act as light-independent inhibitors of CLOCK/BMAL1, thereby suppressing the per genes transcriptions (Sancar, 2000). This auto-regulatory feedback mechanism of clock gene expression serves as the basis for the temporal oscillation of the circadian clock (Hardin, 2006; Xu et al., 2007). REV-ERBA forms an accessory loop which periodically represses transcription of BMAL1, serving to stabilize the oscillator (Guillaumond et al., 2005; Reddy and Maywood, 2007). Although every mammalian cell is believed to express the circadian clock genes, it was held that cells outside the SCN could not maintain self-sustained circadian oscillation in the absence of the SCN (Fukuhara and Tosini, 2003). However, parabiosis studies and isolated cell culture studies clearly indicate that individual tissues can produce sustained intrinsic circadian rhythms independent of the SCN (Nagoshi et al., 2004, 2005; Davidson et al., 2005; Durgan et al., 2005; Guo et al., 2005). However, signals from the SCN or an environmental trigger are required to keep the individual cell rhythms in synchrony with each other. The mechanism of communication between the SCN and the bone marrow which produces regenerative cell populations that may assist in wound healing, the physiologic implications, and means to exploit circadian rhythms for clinical purposes are currently being investigated (Bourin et al., 2002; Tsinkalovsky et al., 2005, 2007; Scadden, 2008). There have been shown to be diurnal variations in granulocyte-colony stimulating factor (G-CSF) that alter the levels of circulating stem cells (Jilma et al., 1999). Mendez-Ferrer et al. (2008) showed that the circadian clock regulates bone marrow-derived SDF-1α via neuronal β3-adrenergic receptors.
It is clear that there is increased understanding of the basic nature by which a rhythmic gene expression can be produced. It is also clear that, other than output from a central clock, the manner by which a given peripheral clock is synchronized with another, or the extent to which a peripheral clock can establish feedback to the SCN that it is, in fact, synchronized is not known. At present, the literature does support the premise that pathophysiologic conditions can both cause uncoupling of peripheral oscillators and be caused by uncoupling of peripheral clocks (Muller, 1999a,b; Young et al., 2001a,b; Willich et al., 2004; Lee et al., 2005; Fujino et al., 2006; Maywood et al., 2010; Tsimakouridze et al., 2012; Reddy and Rey, 2014; Robinson and Reddy, 2014; Wu and Reddy, 2014).
Circadian effects and acute ischemia/reperfusion injury
Ischemia/reperfusion (I/R) injury occurs when an artery that supplies the ventricular tissue becomes obstructed and limits blood flow, and thus oxygen and nutrients as well as waste removal. If this occlusion persists, the damage becomes irreversible. If flow can be reinstated (reperfusion), tissue can be salvaged but there is ancillary oxidative stress (Anaya-Prado et al., 2002; Kaminski et al., 2002; Hamacher-Brady et al., 2006). I/R injury is a complex process involving vascular and endothelial dysfunction, metabolic and mitochondrial dysfunction, necrosis, apoptosis, and functional deficits, even in tissue without permanent cellular injury (Jordan et al., 1999; Giordano, 2005; Seal and Gewertz, 2005; Cohen et al., 2006). A common feature of I/R injury is an inflammatory reaction, with infiltration of polymorphonuclear leukocytes (PMN), predominantly neutrophils which have been causally linked to myocardial damage during reperfusion injury (Jordan et al., 1999). Release of elastases, lipases, and proteases and peroxidases from azurophilic granules of neutrophils as well as reactive oxygen species (ROS) generated by NADPH oxidase in neutrophil membranes can result in direct myocyte damage (Rossi, 1986; Frangogiannis et al., 1996; Takayama et al., 2004). The interaction between neutrophils and endothelial cells is mediated by interactions at the vascular interface of different cell adhesion molecules including selectins, β2-integrins, and the immunoglobulin superfamily (Jones et al., 1999). Hypoxia and cytokines released from ischemic myocardium result in upregulation of these adhesion markers on endothelial surfaces as well as on the surface of neutrophils, thereby facilitating neutrophil recruitment to the tissue during reperfusion (Frangogiannis et al., 1996).
Inflammation plays a key role in the development and progression of myocardial infarction and neutrophil infiltration is a defining feature of ischemic cardiac diseases (Jordan et al., 1999). Reperfusion injury following revascularization procedures is a major cause of myocardial tissue damage, and, accordingly, reperfusion elevates proinflammatory cytokines and infiltration of neutrophils into the tissue (Welbourn et al., 1991; Frangogiannis et al., 1996).IL-1β and TNF-α have direct effects on cardiomyocytes (Suzuki et al., 2001; Chandrasekar et al., 2003), and TNF-α and IL-6 prime inflammatory cells, increasing their response to soluble proinflammatory mediators such as N-formyl peptides, C5a, and platelet-activating factors (Jordan et al., 1999). Infiltrated neutrophils cause tissue destruction by release of elastases, proteases, and superoxide radicals (Rossi, 1986; Rotrosen, 1992; Jordan et al., 1999). Many facets of immune function demonstrate diurnal patterns (Curtis et al., 2014).
Oxidant stress is a finely modulated event in normal physiology. The most common sources of routine oxidant burdens result from normal metabolic activity and mitochondrial electron transfer to molecular oxygen in the mitochondria at complexes I and III of the electron transport chain, producing superoxide and other ROS. Normally, excess ROS is scavenged and neutralized by the actions of enzymes like superoxide dismutase (SOD) and glutathione peroxidase (Taniyama and Griendling, 2003). Melatonin, a hormone with well-established circadian characteristics, has been reported to be a strong regulator of nitric oxide synthase (NOS) (Aydogan et al., 2006). Attenuated increases in night-time melatonin levels in hospitalized patients following angioplasty were correlated positively with increases in C-reactive peptide (CRP), an acute phase inflammatory marker, and were predictive of increased risk of event in the next 6 months (Dominguez-Rodriguez et al., 2006a,b). These findings, suggesting that melatonin is cardioprotective, and are consistent with reports that melatonin is an anti-oxidant, and stimulates anti-oxidant gene production (Hardeland et al., 2003). In isolated rat hearts, melatonin reduced necrosis and infarct size by inhibiting the mitochondrial permeability transition pore (MPTP) opening which reduced NAD+ and cytochrome c release (Petrosillo et al., 2009). However, Genade et al. reported that the addition of melatonin to isolated, perfused rat hearts abolished the cardioprotective effects induced by ischemic pre-conditioning (IPC) (Genade et al., 2006). The effect was attributed to melatonin's free radical scavenging ability, diminishing the level of ROS below those necessary to trigger the cardioprotective response. Nitric oxide, when produced in normal amounts, is an important signaling molecule, but when present in excess amounts may contribute to protein nitrosylation and ROS generation. In vascular disease, uncoupled activity of NOS, or production of ROS in excess of endogenous antioxidant capacity, leads to oxidative stress which turns into an abnormal vascular response (Cohen, 1995; Taniyama and Griendling, 2003; Lyle and Griendling, 2006). In I/R, a cascade of events occurs that prevents proper NOS-protein interactions, altering NOS function and NADPH oxidase activity, thereby altering myocyte function. However, two recent reviews highlight the fact that there remains significant disagreement regarding whether and how NO and isoforms of NOS contribute to, or inhibit cardioprotection, particularly in the setting of IPC (Cohen et al., 2006; Jones and Bolli, 2006). Lapenna et al. reported that glutathione peroxidase activity displayed circadian rhythm in the heart, which corresponded with sensitivity to H2O2-induced oxidative myocardial damage (Lapenna et al., 1992).
Circadian control of homeostatic functions is controlled by environmental and endogenous influences. Circadian genes have the capacity to regulate systems that modulate oxidant burdens, and therefore may potentially contribute significantly to the outcome of I/R or IPC-induced cardioprotection.
A central element of ischemia is hypoxia. The principal oxygen sensing molecule within the myocardium is hypoxia inducible factor 1 alpha (HIF-1α). HIF-1α is a basic helix-loop-helix PAS domain transcription factor. It is present as a cytosolic protein that is constitutively degraded, but under hypoxic conditions is phosphorylated, which stabilizes it, enabling nuclear translocation. In the nucleus HIF-1α forms heterodimers with the aryl hydrocarbon nuclear translocase (ARNT), or HIF-1β, and binds to hypoxia response elements in the promoter region of a wide range of genes, including those regulating angiogenesis vascular endothelial growth factor (VEGF), metabolism (especially genes coding for glycolytic enzymes), apoptosis, and vasomotor reactivity (NOS) (Semenza, 2001; Yamakawa et al., 2003; Giordano, 2005). Of particular note is that there is thought to be considerable homology in the binding characteristics of Per2 and HIF-1α, such that cross talk has been reported between the circadian gene CLOCK, and HIF-1α in the regulation of vasopressin gene (Ghorbel et al., 2003). In addition, Koyonagi et al. reported that Per2 expression attenuated hypoxic induction of VEGF expression in a dose dependent manner (Koyanagi et al., 2003). The presumed mechanism was that Per2 bound to HIF-1α, thus blocking nuclear translocation and preventing HIF-1α induced transcription of VEGF. Constitutively stable hybrids of HIF-1α were cardioprotective in cultured rat cardiomyocyctes exposed to simulated I/R injury (Date et al., 2005) and led to increases in several genes also induced by IPC, including HSP-70. However, HIF-1α also is known to be overexpressed in heart failure, which could represent a failure of a sustained attempt to compensate, or it could be that long-term expression is maladaptive. The literature does not yet provide a clear indication which is more likely (Giordano, 2005).
Perhaps the most potent cardioprotection is mediated by signaling cascades activated by IPC, and more recently as described in association with ischemic post-conditioning as well. As reperfusion injury is multi-faceted, it appears that biologic preconditioning is capable of inducing protective responses that also are multi-faceted. Among many mechanisms associated with IPC, activation of the AKT, MAPK, Mek-Erk1/2 pathways, PKCε, HSP 70, mitochondrial KATP channels, GSK-3β, and HIF-1α regulated genes all have been implicated (Murphy, 2004; Hausenloy et al., 2005; Crisostomo et al., 2006; Zhao and Vinten-Johansen, 2006; Das et al., 2008; Wong et al., 2010). The mitochondria, the source of ATP for the cardiomyocyte, also generate ROS when the tissue is damaged and so much research is aimed at improving mitochondrial energy production and reduce apoptosis to reduce infarct size (Di Lisa et al., 1998; Oldenburg et al., 2002; Krieg et al., 2003; Marin-Garcia and Goldenthal, 2004; Costa et al., 2005; Murphy and Steenbergen, 2007). Inhibiting the phosphorylation of glycogen synthase beta (GSK-3β) has been shown to reduce I/R injury but the mechanism have not yet been fully elucidated (Tong et al., 2002; Gross et al., 2004, 2006, 2007; Murphy and Steenbergen, 2005; Mozaffari and Schaffer, 2008; Omar et al., 2010). Possibilities include modulation of mitochondrial function via the MPTP and the voltage-dependent anion channel (VDAC) but further investigation to illuminate the pathway is needed (Mattson and Kroemer, 2003; Marin-Garcia and Goldenthal, 2004; Di Lisa et al., 2007; Schwertz et al., 2007; Costa and Garlid, 2008; Das et al., 2008; Garlid et al., 2009).
The presumed benefit of independent peripheral oscillators is the ability to anticipate, at the cellular level, changes driven by the SCN in response to environmental cues. Cardiac tissue expresses all known isoforms of
cryand
pergenes, with
cry2,
per1, and
per2expressed to the greatest degree (Young,
2006). Elements of functioning circadian oscillators are present in cardiac tissue cells:
Vascular endothelium and smooth muscle show significant circadian variability in functional response (Nonaka et al., 2001; Kawano and Ogawa, 2005; Tsujino et al., 2005; Walters et al., 2006; Viswambharan et al., 2007; Yagita et al., 2010) and dysfunction of these cells types are characteristics of I/R injury (Hazarika et al., 2004; Cozzi et al., 2006).
Fibroblasts, cells intimately involved in remodeling post-infarction myocardium (Chintalgattu and Katwa, 2004; Squires et al., 2005), show robust circadian responses in culture (Chintalgattu and Katwa, 2004; Nagoshi et al., 2004, 2005; Squires et al., 2005).
Per2 also has been shown recently to modulate cytokine release in some inflammatory cells (Liu et al., 2006), and inflammation responses are common feature of I/R injury (Welbourn et al., 1991; Jordan et al., 1999; Albert, 2000; Frangogiannis et al., 2002; Albert et al., 2003; Hazarika et al., 2004; Cozzi et al., 2006; Liu et al., 2006).
Circadian genes appear to regulate a panel of genes encoding for cardiac metabolic enzymes, and it has been postulated that a major role for circadian genes in heart is to synchronize cardiomyocyte metabolic activity (fatty acid vs. glycolytic preferences) with dietary meal induced oscillations in plasma substrate availability. The ability to shift substrates from fatty acid to glycolytic sources is an important characteristic determining functional recovery from I/R injury (Stanley, 2004; Sambandam et al., 2006).
Recent studies examining the role of mPer2 in vivo are conflicting. We have shown that mPer2-mutant mice had less severe injury in acute I/R and chronically non-reperfused MI (Virag et al., 2010, 2013). Conversely, Eckle's group has shown that Per2 is cardioprotective and this tolerance may be by virtue of adenosine-elicited stabilization of Per2, modulation of metabolism, and/or inflammation (Eckle et al., 2012; Bonney et al., 2013a,b; Eltzschig et al., 2013). Lipkova et al. showed that Per3 VNTR polymorphism in humans influences the onset of pain associated with acute MI (Lipkova et al., 2014). Alibhai et al. recently demonstrated that post-MI remodeling is worsened by circadian rhythm disruption (Alibhai et al., 2014).
There is clearly a strong confluence between cascades participating in I/R injury and those regulated by circadian genes. Specific and comprehensive studies examining the effects of each circadian gene and/or circadian rhythm variations on myocardial I/R injury, its modulation by IPC, and how these acute responses might influence the subsequent post-infarction remodeling are only recently beginning to be addressed.
Chronic myocardial infarct repair and circadian rhythm genes
Myocardial infarction is an inflammatory disease. Irreversible ischemic injury begins within 20 min of severe ischemia in vivo and is complete within an hour (Holmes et al., 2005). Myocyte, fibroblast, vascular smooth muscle, and endothelial cell death progresses as a wavefront from subendocardial to subepicardial wall (Reimer and Jennings, 1979). Within 24 h, neutrophils infiltrate from the periphery and macrophages follow within 48 h. Neutrophils gradually apoptose by 5 days but macrophages persist in the infarct throughout repair. The breakdown of intercellular collagen fibrils begins by post-translational activation of matrixmetalloproteinases (MMPs). The increased ratio of MMPs relative to tissue inhibitors of matrixmetalloproteinases (TIMPs) propagates this degradation that begins within hours and proceeds for 3–4 days (Vanhoutte et al., 2006). As the matrix disintegrates, myocyte slippage occurs (Cleutjens et al., 1995). Myocyte necrosis, evidenced by contraction bands and pyknosis, as well as dead vascular elements are completely phagocytosed by macrophages within 2 weeks (Baroldi, 1988; Virag and Murry, 2003; Holmes et al., 2005). Between 4 and 7 days granulation tissue, comprised of proliferating fibroblasts and endothelial cells, forms by migration of these cells from the border zone into the infarct core (Virag and Murry, 2003). During this process, a variety of factors are evolved from macrophages, including chemokines such as MCP-1, cytokines such as IL-1 and G-CSF, and ROS such as nitric oxide and superoxide anion (Byrne et al., 2003; Kumar and Jugdutt, 2003; Nian et al., 2004; Frangogiannis and Entman, 2005; Frangogiannis, 2006; Maulik, 2006). These molecules can also cause considerable damage to surrounding viable cells and result in further spreading of the infarct. By 2 weeks, the young scar is characterized by the parallel organization of fibroblasts and predominance of Type I fibrillar collagen (Sun et al., 2002; Virag and Murry, 2003). As the matrix becomes increasingly more fibrotic, endothelial cells, fibroblasts and macrophages begin to apoptose, resulting in vascular regression (Frangogiannis et al., 2002; Virag and Murry, 2003). Further, perivascular fibrosis and disarrayed hypertrophy will not be balanced by the coronary blood flow reserve and the consequent hypoperfusion may cause myocardial ischemia. Progressive thinning and stretching of the non-contractile scar tissue continues, resulting in increased chamber dimensions and increased wall stress. Subsequent volume-overload hypertrophy of the surviving myocardium ensues, but this is insufficient to maintain pressure development. Ultimately, this leads to inadequate pumping and overt heart failure (Pfeffer and Braunwald, 1990; Opie et al., 2006). Cardiac hypertrophy and failure also entail dysfunction of mitochondrial energy and substrate metabolism. Impaired mitochondrial function is associated with a decline in high-energy phosphates, reduced oxygen consumption, and decreased expression and activity of complexes I through IV of the respiratory chain. Therefore, the signaling cascades described above that are active during preconditioning should also be investigated as remodeling progresses. Since circadian clocks in peripheral tissues can disturb and be disturbed by genetic and/or lifestyle- related pathologies, modulation of these mediators may be potentially exploited as novel chronotherapeutic targets for treatment and prevention of these conditions.
Conclusion
A complex sequence of various cellular activities orchestrate myocardial infarct injury and healing. The importance of circadian genes and/or rhythms is also evident, however, the precise mechanisms are only beginning to be addressed. In depth analyses of macrophage, endothelial cell, and fibroblast behavior in vivo in both the acute and chronic phases of infarct repair in genetically modified mice (tissue-specific and global) as well as carefully constructed approaches to sort out cause and effect with respect to circadian genes, rhythm variations, and injury will illuminate signaling cascades that may potentially be exploited to yield more efficacious myocardial infarct healing. This information can then be applied to mitigate myocardial infarction in the presence of pathologies and other confounding variables that may be involved in governing disease severity and progression.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Albert M. A. (2000). The role of C-reactive protein in cardiovascular disease risk. Curr. Cardiol. Rep. 2, 274–279. 10.1007/s11886-000-0081-7
2
Albert M. A. Glynn R. J. Ridker P. M. (2003). Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation108, 161–165. 10.1161/01.CIR.0000080289.72166.CF
3
Alibhai F. J. Tsimakouridze E. V. Chinnappareddy N. Wright D. C. Billia F. O'Sullivan M. L. et al . (2014). Short-term disruption of diurnal rhythms after murine myocardial infarction adversely affects long-term myocardial structure and function. Circ. Res. 114, 1713–1722. 10.1161/CIRCRESAHA.114.302995
4
Anaya-Prado R. Toledo-Pereyra L. H. Lentsch A. B. Ward P. A. (2002). Ischemia/reperfusion injury. J. Surg. Res. 105, 248–258. 10.1006/jsre.2002.6385
5
Aydogan S. Yerer M. B. Goktas A. (2006). Melatonin and nitric oxide. J. Endocrinol. Invest. 29, 281–287. 10.1007/BF03345555
6
Bailey S. M. Udoh U. S. Young M. E. (2014). Circadian regulation of metabolism. J. Endocrinol. 222, R75–R96. 10.1530/JOE-14-0200
7
Balsalobre A. Brown S. A. Marcacci L. Tronche F. Kellendonk C. Reichardt H. M. et al . (2000). Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science289, 2344–2347. 10.1126/science.289.5488.2344
8
Baroldi G. (1988). Anatomy and quantification of myocardial cell death. Methods Achiev. Exp. Pathol. 13, 87–113.
9
Bonney S. Hughes K. Harter P. N. Mittelbronn M. Walker L. Eckle T. (2013a). Cardiac period 2 in myocardial ischemia: clinical implications of a light dependent protein. Int. J. Biochem. Cell Biol. 45, 667–671. 10.1016/j.biocel.2012.12.022
10
Bonney S. Kominsky D. Brodsky K. Eltzschig H. Walker L. Eckle T. (2013b). Cardiac Per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart. PLoS ONE8:e71493. 10.1371/journal.pone.0071493
11
Bourin P. Ledain A. F. Beau J. Mille D. Levi F. (2002). In-vitro circadian rhythm of murine bone marrow progenitor production. Chronobiol. Int. 19, 57–67. 10.1081/CBI-120002677
12
Bray M. S. Young M. E. (2007). Circadian rhythms in the development of obesity: potential role for the circadian clock within the adipocyte. Obes. Rev. 8, 169–181. 10.1111/j.1467-789X.2006.00277.x
13
Byrne J. A. Grieve D. J. Cave A. C. Shah A. M. (2003). Oxidative stress and heart failure. Arch. Mal. Coeur Vaiss. 96, 214–221.
14
Chandrasekar B. Colston J. T. De La Rosa S. D. Rao P. P. Freeman G. L. (2003). TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochem. Biophys. Res. Commun. 303, 1152–1158. 10.1016/S0006-291X(03)00496-0
15
Chintalgattu V. Katwa L. C. (2004). Role of protein kinase Cdelta in endothelin-induced type I collagen expression in cardiac myofibroblasts isolated from the site of myocardial infarction. J. Pharmacol. Exp. Ther. 311, 691–699. 10.1124/jpet.104.070151
16
Chu L. W. Zhu Y. Yu K. Zheng T. Yu H. Zhang Y. et al . (2008). Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 11, 342–348. 10.1038/sj.pcan.4501024
17
Clairambault J. (2008). A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation. IEEE Eng. Med. Biol. Mag. 27, 20–24. 10.1109/MEMB.2007.907363
18
Cleutjens J. P. Kandala J. C. Guarda E. Guntaka R. V. Weber K. T. (1995). Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol. 27, 1281–1292. 10.1016/S0022-2828(05)82390-9
19
Cohen M. V. Yang X. M. Downey J. M. (2006). Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc. Res. 70, 231–239. 10.1016/j.cardiores.2005.10.021
20
Cohen R. A. (1995). The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. 38, 105–128. 10.1016/S0033-0620(05)80002-7
21
Corwin J. V. Vargo J. M. (1993). Light deprivation produces accelerated behavioral recovery of function from neglect produced by unilateral medial agranular prefrontal cortex lesions in rats. Behav. Brain Res. 56, 187–196. 10.1016/0166-4328(93)90038-R
22
Costa A. D. Garlid K. D. (2008). Intramitochondrial signaling: interactions among mitoKATP, PKCepsilon, ROS, and MPT. Am. J. Physiol. Heart Circ. Physiol. 295, H874–H882. 10.1152/ajpheart.01189.2007
23
Costa A. D. Garlid K. D. West I. C. Lincoln T. M. Downey J. M. Cohen M. V. et al . (2005). Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ. Res. 97, 329–336. 10.1161/01.RES.0000178451.08719.5b
24
Cozzi E. Hazarika S. Stallings H. W. 3rd. Cascio W. E. Devlin R. B. Lust R. M. et al . (2006). Ultrafine particulate matter exposure augments ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol. 291, H894–H903. 10.1152/ajpheart.01362.2005
25
Crisostomo P. R. Wairiuko G. M. Wang M. Tsai B. M. Morrell E. D. Meldrum D. R. (2006). Preconditioning versus postconditioning: mechanisms and therapeutic potentials. J. Am. Coll. Surg. 202, 797–812. 10.1016/j.jamcollsurg.2005.12.002
26
Curtis A. M. Bellet M. M. Sassone-Corsi P. O'Neill L. A. (2014). Circadian clock proteins and immunity. Immunity40, 178–186. 10.1016/j.immuni.2014.02.002
27
Dardente H. Cermakian N. (2005). [How many pieces to build a circadian clock?]. Med. Sci. (Paris)21, 66–72. 10.1051/medsci/200521166
28
Das S. Wong R. Rajapakse N. Murphy E. Steenbergen C. (2008). Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ. Res. 103, 983–991. 10.1161/CIRCRESAHA.108.178970
29
Date T. Mochizuki S. Belanger A. J. Yamakawa M. Luo Z. Vincent K. A. et al . (2005). Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am. J. Physiol. Cell Physiol. 288, C314–C320. 10.1152/ajpcell.00374.2004
30
Davidson A. J. London B. Block G. D. Menaker M. (2005). Cardiovascular tissues contain independent circadian clocks. Clin. Exp. Hypertens. 27, 307–311. 10.1081/CEH-48933
31
De Luca G. Suryapranata H. Ottervanger J. P. Van't Hof A. W. Hoorntje J. C. Gosselink A. T. et al . (2005). Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am. Heart J. 150, 1185–1189. 10.1016/j.ahj.2005.01.057
32
Decoursey P. J. Walker J. K. Smith S. A. (2000). A circadian pacemaker in free-living chipmunks: essential for survival?J. Comp. Physiol. A186, 169–180. 10.1007/s003590050017
33
Di Lisa F. Canton M. Menabo R. Kaludercic N. Bernardi P. (2007). Mitochondria and cardioprotection. Heart Fail. Rev. 12, 249–260. 10.1007/s10741-007-9028-z
34
Di Lisa F. Menabo R. Canton M. Petronilli V. (1998). The role of mitochondria in the salvage and the injury of the ischemic myocardium. Biochim. Biophys. Acta1366, 69–78. 10.1016/S0005-2728(98)00121-2
35
Ding J. M. Chen D. Weber E. T. Faiman L. E. Rea M. A. Gillette M. U. (1994). Resetting the biological clock: mediation of nocturnal circadian shifts by glutamate and NO. Science266, 1713–1717. 10.1126/science.7527589
36
Dominguez-Rodriguez A. Abreu-Gonzalez P. Garcia-Gonzalez M. Reiter R. J. (2006a). Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 97, 1162–1164. 10.1016/j.amjcard.2005.11.033
37
Dominguez-Rodriguez A. Garcia-Gonzalez M. Abreu-Gonzalez P. Ferrer J. Kaski J. C. (2006b). Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 97, 10–12. 10.1016/j.amjcard.2005.07.120
38
Durgan D. J. Hotze M. A. Tomlin T. M. Egbejimi O. Graveleau C. Abel E. D. et al . (2005). The intrinsic circadian clock within the cardiomyocyte. Am. J. Physiol. Heart Circ. Physiol. 289, H1530–H1541. 10.1152/ajpheart.00406.2005
39
Durgan D. J. Young M. E. (2010). The cardiomyocyte circadian clock: emerging roles in health and disease. Circ. Res. 106, 647–658. 10.1161/CIRCRESAHA.109.209957
40
Dvornyk V. Vinogradova O. Nevo E. (2003). Origin and evolution of circadian clock genes in prokaryotes. Proc. Natl. Acad. Sci. U.S.A. 100, 2495–2500. 10.1073/pnas.0130099100
41
Eckle T. Hartmann K. Bonney S. Reithel S. Mittelbronn M. Walker L. A. et al . (2012). Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat. Med. 18, 774–782. 10.1038/nm.2728
42
Eltzschig H. K. Bonney S. K. Eckle T. (2013). Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol. Med. 19, 345–354. 10.1016/j.molmed.2013.02.005
43
Frangogiannis N. G. (2006). The mechanistic basis of infarct healing. Antioxid. Redox Signal. 8, 1907–1939. 10.1089/ars.2006.8.1907
44
Frangogiannis N. G. Entman M. L. (2005). Chemokines in myocardial ischemia. Trends Cardiovasc. Med. 15, 163–169. 10.1016/j.tcm.2005.06.005
45
Frangogiannis N. G. Smith C. W. Entman M. L. (2002). The inflammatory response in myocardial infarction. Cardiovasc. Res. 53, 31–47. 10.1016/S0008-6363(01)00434-5
46
Frangogiannis N. G. Youker K. A. Entman M. L. (1996). The role of the neutrophil in myocardial ischemia and reperfusion. EXS76, 263–284.
47
Fujino Y. Iso H. Tamakoshi A. Inaba Y. Koizumi A. Kubo T. et al . (2006). A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. Am. J. Epidemiol. 164, 128–135. 10.1093/aje/kwj185
48
Fukuhara C. Tosini G. (2003). Peripheral circadian oscillators and their rhythmic regulation. Front. Biosci. 8, d642–d651. 10.2741/1042
49
Garlid K. D. Costa A. D. Quinlan C. L. Pierre S. V. Dos Santos P. (2009). Cardioprotective signaling to mitochondria. J. Mol. Cell. Cardiol. 46, 858–866. 10.1016/j.yjmcc.2008.11.019
50
Genade S. Ytrehus K. Lochner A. (2006). Melatonin prevents cardioprotection induced by a multi-cycle ischaemic preconditioning protocol in the isolated perfused rat heart. Cardiovasc. J. S. Afr. 17, 239–244.
51
Ghorbel M. T. Coulson J. M. Murphy D. (2003). Cross-talk between hypoxic and circadian pathways: cooperative roles for hypoxia-inducible factor 1alpha and CLOCK in transcriptional activation of the vasopressin gene. Mol. Cell. Neurosci. 22, 396–404. 10.1016/S1044-7431(02)00019-2
52
Giordano F. J. (2005). Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115, 500–508. 10.1172/JCI200524408
53
Glossop N. R. Lyons L. C. Hardin P. E. (1999). Interlocked feedback loops within the Drosophila circadian oscillator. Science286, 766–768. 10.1126/science.286.5440.766
54
Granados-Fuentes D. Herzog E. D. (2013). The clock shop: coupled circadian oscillators. Exp. Neurol. 243, 21–27. 10.1016/j.expneurol.2012.10.011
55
Granda T. G. Liu X. H. Smaaland R. Cermakian N. Filipski E. Sassone-Corsi P. et al . (2005). Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J. 19, 304–306. 10.1096/fj.04-2665fje
56
Green C. B. Takahashi J. S. Bass J. (2008). The meter of metabolism. Cell134, 728–742. 10.1016/j.cell.2008.08.022
57
Gross E. R. Hsu A. K. Gross G. J. (2004). Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 94, 960–966. 10.1161/01.RES.0000122392.33172.09
58
Gross E. R. Hsu A. K. Gross G. J. (2006). The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am. J. Physiol. Heart Circ. Physiol. 291, H827–H834. 10.1152/ajpheart.00003.2006
59
Gross E. R. Hsu A. K. Gross G. J. (2007). GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res. Cardiol. 102, 341–349. 10.1007/s00395-007-0651-6
60
Guillaumond F. Dardente H. Giguere V. Cermakian N. (2005). Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J. Biol. Rhythms20, 391–403. 10.1177/0748730405277232
61
Guo H. Brewer J. M. Champhekar A. Harris R. B. Bittman E. L. (2005). Differential control of peripheral circadian rhythms by suprachiasmatic-dependent neural signals. Proc. Natl. Acad. Sci. U.S.A. 102, 3111–3116. 10.1073/pnas.0409734102
62
Gupta A. Shetty H. (2005). Circadian variation in stroke—a prospective hospital-based study. Int. J. Clin. Pract. 59, 1272–1275. 10.1111/j.1368-5031.2005.00678.x
63
Hamacher-Brady A. Brady N. R. Gottlieb R. A. (2006). The interplay between pro-death and pro-survival signaling pathways in myocardial ischemia/reperfusion injury: apoptosis meets autophagy. Cardiovasc. Drugs Ther. 20, 445–462. 10.1007/s10557-006-0583-7
64
Hardeland R. Coto-Montes A. Poeggeler B. (2003). Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol. Int. 20, 921–962. 10.1081/CBI-120025245
65
Hardin P. E. (2006). Essential and expendable features of the circadian timekeeping mechanism. Curr. Opin. Neurobiol. 16, 686–692. 10.1016/j.conb.2006.09.001
66
Hardin P. E. Glossop N. R. (1999). Perspectives: neurobiology. The CRYs fo flies and mice. Science286, 2460–2461. 10.1126/science.286.5449.2460
67
Hardin P. E. Panda S. (2013). Circadian timekeeping and output mechanisms in animals. Curr. Opin. Neurobiol. 23, 724–731. 10.1016/j.conb.2013.02.018
68
Harmer S. L. Panda S. Kay S. A. (2001). Molecular bases of circadian rhythms. Annu. Rev. Cell Dev. Biol. 17, 215–253. 10.1146/annurev.cellbio.17.1.215
69
Hausenloy D. J. Tsang A. Yellon D. M. (2005). The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15, 69–75. 10.1016/j.tcm.2005.03.001
70
Hazarika S. Van Scott M. R. Lust R. M. (2004). Myocardial ischemia-reperfusion injury is enhanced in a model of systemic allergy and asthma. Am. J. Physiol. Heart Circ. Physiol. 286, H1720–H1725. 10.1152/ajpheart.01064.2003
71
Herzog E. D. Schwartz W. J. (2002). A neural clockwork for encoding circadian time. J. Appl. Physiol. 92, 401–408. 10.1152/japplphysiol.00836.2001
72
Holmes J. W. Borg T. K. Covell J. W. (2005). Structure and mechanics of healing myocardial infarcts. Annu. Rev. Biomed. Eng. 7, 223–253. 10.1146/annurev.bioeng.7.060804.100453
73
Honma S. Ikeda M. Abe H. Tanahashi Y. Namihira M. Honma K. et al . (1998). Circadian oscillation of BMAL1, a partner of a mammalian clock gene Clock, in rat suprachiasmatic nucleus. Biochem. Biophys. Res. Commun. 250, 83–87. 10.1006/bbrc.1998.9275
74
Izzedine H. Launay-Vacher V. Deray G. (2006). Abnormal blood pressure circadian rhythm: a target organ damage?Int. J. Cardiol. 107, 343–349. 10.1016/j.ijcard.2005.03.046
75
Jeyaraj D. Haldar S. M. Wan X. McCauley M. D. Ripperger J. A. Hu K. et al . (2012). Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature483, 96–99. 10.1038/nature10852
76
Jilma B. Hergovich N. Stohlawetz P. Eichler H. G. Bauer P. Wagner O. F. (1999). Circadian variation of granulocyte colony stimulating factor levels in man. Br. J. Haematol. 106, 368–370. 10.1046/j.1365-2141.1999.01543.x
77
Jones S. P. Bolli R. (2006). The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16–23. 10.1016/j.yjmcc.2005.09.011
78
Jones S. P. Girod W. G. Granger D. N. Palazzo A. J. Lefer D. J. (1999). Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am. J. Physiol. 277, H763–H769.
79
Jordan J. E. Zhao Z. Q. Vinten-Johansen J. (1999). The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43, 860–878. 10.1016/S0008-6363(99)00187-X
80
Kaminski K. A. Bonda T. A. Korecki J. Musial W. J. (2002). Oxidative stress and neutrophil activation–the two keystones of ischemia/reperfusion injury. Int. J. Cardiol. 86, 41–59. 10.1016/S0167-5273(02)00189-4
81
Kanth R. Ittaman S. Rezkalla S. (2013). Circadian patterns of ST elevation myocardial infarction in the new millennium. Clin. Med. Res. 11, 66–72. 10.3121/cmr.2013.1120
82
Kawachi I. Colditz G. A. Stampfer M. J. Willett W. C. Manson J. E. Speizer F. E. et al . (1995). Prospective study of shift work and risk of coronary heart disease in women. Circulation92, 3178–3182. 10.1161/01.CIR.92.11.3178
83
Kawano H. Ogawa H. (2005). Endothelial function and coronary spastic angina. Intern. Med. 44, 91–99. 10.2169/internalmedicine.44.91
84
Knutsson A. Akerstedt T. Jonsson B. G. Orth-Gomer K. (1986). Increased risk of ischaemic heart disease in shift workers. Lancet2, 89–92. 10.1016/S0140-6736(86)91619-3
85
Koyanagi S. Kuramoto Y. Nakagawa H. Aramaki H. Ohdo S. Soeda S. et al . (2003). A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 63, 7277–7283.
86
Krieg T. Cohen M. V. Downey J. M. (2003). Mitochondria and their role in preconditioning's trigger phase. Basic Res. Cardiol. 98, 228–234. 10.1007/s00395-003-0422-y
87
Kumar D. Jugdutt B. I. (2003). Apoptosis and oxidants in the heart. J. Lab. Clin. Med. 142, 288–297. 10.1016/S0022-2143(03)00148-3
88
Kume K. Zylka M. J. Sriram S. Shearman L. P. Weaver D. R. Jin X. et al . (1999). mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell98, 193–205. 10.1016/S0092-8674(00)81014-4
89
Kyriacou C. P. Hall J. C. (1980). Circadian rhythm mutations in Drosophila melanogaster affect short-term fluctuations in the male's courtship song. Proc. Natl. Acad. Sci. U.S.A. 77, 6729–6733. 10.1073/pnas.77.11.6729
90
Lapenna D. De Gioia S. Mezzetti A. Porreca E. Ciofani G. Marzio L. et al . (1992). Circadian variations in antioxidant defences and lipid peroxidation in the rat heart. Free Radic. Res. Commun. 17, 187–194. 10.3109/10715769209068165
91
Lee C. Etchegaray J. P. Cagampang F. R. Loudon A. S. Reppert S. M. (2001). Posttranslational mechanisms regulate the mammalian circadian clock. Cell107, 855–867. 10.1016/S0092-8674(01)00610-9
92
Lee K. W. Blann A. D. Lip G. Y. (2005). High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am. J. Hypertens. 18, 104–115. 10.1016/j.amjhyper.2004.09.003
93
Lemmer B. (2006). The importance of circadian rhythms on drug response in hypertension and coronary heart disease–from mice and man. Pharmacol. Ther. 111, 629–651. 10.1016/j.pharmthera.2005.11.008
94
Lipkova J. Splichal Z. Bienertova-Vasku J. A. Jurajda M. Parenica J. Vasku A. et al . (2014). Period3 VNTR polymorphism influences the time-of-day pain onset of acute myocardial infarction with ST elevation. Chronobiol. Int. 31, 878–890. 10.3109/07420528.2014.921790
95
Liu J. Mankani G. Shi X. Meyer M. Cunningham-Runddles S. Ma X. et al . (2006). The circadian clock Period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect. Immun. 74, 4750–4756. 10.1128/IAI.00287-06
96
Lopez F. Lee K. W. Marin F. Roldan V. Sogorb F. Caturla J. et al . (2005). Are there ethnic differences in the circadian variation in onset of acute myocardial infarction? A comparison of 3 ethnic groups in Birmingham, UK and Alicante, Spain. Int. J. Cardiol. 100, 151–154. 10.1016/j.ijcard.2004.12.002
97
Lyle A. N. Griendling K. K. (2006). Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda)21, 269–280. 10.1152/physiol.00004.2006
98
Marin-Garcia J. Goldenthal M. J. (2004). Mitochondria play a critical role in cardioprotection. J. Card. Fail. 10, 55–66. 10.1016/S1071-9164(03)00129-5
99
Martino T. A. Oudit G. Y. Herzenberg A. M. Tata N. Koletar M. M. Kabir G. M. et al . (2008). Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R1675–R1683. 10.1152/ajpregu.00829.2007
100
Martino T. A. Tata N. Belsham D. D. Chalmers J. Straume M. Lee P. et al . (2007). Disturbed diurnal rhythm alters gene expression and exacerbates cardiovascular disease with rescue by resynchronization. Hypertension49, 1104–1113. 10.1161/HYPERTENSIONAHA.106.083568
101
Mattson M. P. Kroemer G. (2003). Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9, 196–205. 10.1016/S1471-4914(03)00046-7
102
Maulik N. (2006). Reactive oxygen species drives myocardial angiogenesis?Antioxid. Redox Signal. 8, 2161–2168. 10.1089/ars.2006.8.2161
103
Maury E. Ramsey K. M. Bass J. (2010). Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ. Res. 106, 447–462. 10.1161/CIRCRESAHA.109.208355
104
Maywood E. S. Fraenkel E. McAllister C. J. Wood N. Reddy A. B. Hastings M. H. et al . (2010). Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding. J. Neurosci. 30, 10199–10204. 10.1523/JNEUROSCI.1694-10.2010
105
McNamara P. Seo S. P. Rudic R. D. Sehgal A. Chakravarti D. Fitzgerald G. A. (2001). Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell105, 877–889. 10.1016/S0092-8674(01)00401-9
106
Mendez-Ferrer S. Lucas D. Battista M. Frenette P. S. (2008). Haematopoietic stem cell release is regulated by circadian oscillations. Nature452, 442–447. 10.1038/nature06685
107
Merrow M. Spoelstra K. Roenneberg T. (2005). The circadian cycle: daily rhythms from behaviour to genes. EMBO Rep. 6, 930–935. 10.1038/sj.embor.7400541
108
Morgan T. O. (2002). Is non-dipping status a predictor of cardiac morbidity?J. Hypertens. 20, 1469–1471. 10.1097/00004872-200208000-00003
109
Mormont M. C. Waterhouse J. Bleuzen P. Giacchetti S. Jami A. Bogdan A. et al . (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6, 3038–3045.
110
Mosendane T. Raal F. J. (2008). Shift work and its effects on the cardiovascular system. Cardiovasc. J. Afr. 19, 210–215.
111
Mozaffari M. S. Schaffer S. W. (2008). Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3beta: interaction with the MPT pore. Am. J. Hypertens. 21, 570–575. 10.1038/ajh.2008.25
112
Mukamal K. J. Muller J. E. Maclure M. Sherwood J. B. Mittleman M. A. (2000). Increased risk of congestive heart failure among infarctions with nighttime onset. Am. Heart J. 140, 438–442. 10.1067/mhj.2000.108830
113
Muller J. E. (1999a). Circadian variation and triggering of acute coronary events. Am. Heart J. 137, S1–S8. 10.1016/S0002-8703(99)70390-X
114
Muller J. E. (1999b). Circadian variation in cardiovascular events. Am. J. Hypertens. 12, 35S–42S.
115
Murphy E. (2004). Inhibit GSK-3beta or there's heartbreak dead ahead. J. Clin. Invest. 113, 1526–1528. 10.1172/JCI21986
116
Murphy E. Steenbergen C. (2005). Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition. Expert Opin. Ther. Targets9, 447–456. 10.1517/14728222.9.3.447
117
Murphy E. Steenbergen C. (2007). Preconditioning: the mitochondrial connection. Annu. Rev. Physiol. 69, 51–67. 10.1146/annurev.physiol.69.031905.163645
118
Nagoshi E. Brown S. A. Dibner C. Kornmann B. Schibler U. (2005). Circadian gene expression in cultured cells. Meth. Enzymol. 393, 543–557. 10.1016/S0076-6879(05)93028-0
119
Nagoshi E. Saini C. Bauer C. Laroche T. Naef F. Schibler U. (2004). Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell119, 693–705. 10.1016/j.cell.2004.11.015
120
Naito Y. Tsujino T. Kawasaki D. Okumura T. Morimoto S. Masai M. et al . (2003). Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. J. Hypertens. 21, 1107–1115. 10.1097/00004872-200306000-00010
121
Nedeltcheva A. V. Scheer F. A. (2014). Metabolic effects of sleep disruption, links to obesity and diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 21, 293–298. 10.1097/MED.0000000000000082
122
Nian M. Lee P. Khaper N. Liu P. (2004). Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94, 1543–1553. 10.1161/01.RES.0000130526.20854.fa
123
Nonaka H. Emoto N. Ikeda K. Fukuya H. Rohman M. S. Raharjo S. B. et al . (2001). Angiotensin II induces circadian gene expression of clock genes in cultured vascular smooth muscle cells. Circulation104, 1746–1748. 10.1161/hc4001.098048
124
Oldenburg O. Cohen M. V. Yellon D. M. Downey J. M. (2002). Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc. Res. 55, 429–437. 10.1016/S0008-6363(02)00439-X
125
Omar M. A. Wang L. Clanachan A. S. (2010). Cardioprotection by GSK-3 Inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload. Cardiovasc. Res. 86, 478–486. 10.1093/cvr/cvp421
126
Opie L. H. Commerford P. J. Gersh B. J. Pfeffer M. A. (2006). Controversies in ventricular remodelling. Lancet367, 356–367. 10.1016/S0140-6736(06)68074-4
127
Petrosillo G. Colantuono G. Moro N. Ruggiero F. M. Tiravanti E. Di Venosa N. et al . (2009). Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am. J. Physiol. Heart Circ. Physiol. 297, H1487–H1493. 10.1152/ajpheart.00163.2009
128
Pfeffer M. A. Braunwald E. (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation81, 1161–1172. 10.1161/01.CIR.81.4.1161
129
Prasai M. J. George J. T. Scott E. M. (2008). Molecular clocks, type 2 diabetes and cardiovascular disease. Diab. Vasc. Dis. Res. 5, 89–95. 10.3132/dvdr.2008.015
130
Reddy A. B. Maywood E. S. (2007). Circadian rhythms: per2bations in the liver clock. Curr. Biol. 17, R292–R294. 10.1016/j.cub.2007.02.031
131
Reddy A. B. Rey G. (2014). Metabolic and nontranscriptional circadian clocks: eukaryotes. Annu. Rev. Biochem. 83, 165–189. 10.1146/annurev-biochem-060713-035623
132
Reick M. Garcia J. A. Dudley C. McKnight S. L. (2001). NPAS2: an analog of clock operative in the mammalian forebrain. Science293, 506–509. 10.1126/science.1060699
133
Reimer K. A. Jennings R. B. (1979). The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab. Invest. 40, 633–644.
134
Reppert S. M. Weaver D. R. (2002). Coordination of circadian timing in mammals. Nature418, 935–941. 10.1038/nature00965
135
Robinson I. Reddy A. B. (2014). Molecular mechanisms of the circadian clockwork in mammals. FEBS Lett. 588, 2477–2483. 10.1016/j.febslet.2014.06.005
136
Rossi F. (1986). The O2- -forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function. Biochim. Biophys. Acta853, 65–89. 10.1016/0304-4173(86)90005-4
137
Rotrosen D. (1992). The Respiratory Burst Oxidase. New York, NY: Raven.
138
Ruger M. Scheer F. A. (2009). Effects of circadian disruption on the cardiometabolic system. Rev. Endocr. Metab. Disord. 10, 245–260. 10.1007/s11154-009-9122-8
139
Sambandam N. Morabito D. Wagg C. Finck B. N. Kelly D. P. Lopaschuk G. D. (2006). Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am. J. Physiol. Heart Circ. Physiol. 290, H87–H95. 10.1152/ajpheart.00285.2005
140
Sancar A. (2000). Cryptochrome: the second photoactive pigment in the eye and its role in circadian photoreception. Annu. Rev. Biochem. 69, 31–67. 10.1146/annurev.biochem.69.1.31
141
Sangoram A. M. Saez L. Antoch M. P. Gekakis N. Staknis D. Whiteley A. et al . (1998). Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron21, 1101–1113. 10.1016/S0896-6273(00)80627-3
142
Savopoulos C. Ziakas A. Hatzitolios A. Delivoria C. Kounanis A. Mylonas S. et al . (2006). Circadian rhythm in sudden cardiac death: a retrospective study of 2,665 cases. Angiology57, 197–204. 10.1177/000331970605700210
143
Scadden D. T. (2008). Circadian rhythms: stem cells traffic in time. Nature452, 416–417. 10.1038/452416a
144
Schwertz H. Carter J. M. Abdudureheman M. Russ M. Buerke U. Schlitt A. et al . (2007). Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor. Proteomics7, 4579–4588. 10.1002/pmic.200700734
145
Seal J. B. Gewertz B. L. (2005). Vascular dysfunction in ischemia-reperfusion injury. Ann. Vasc. Surg. 19, 572–584. 10.1007/s10016-005-4616-7
146
Semenza G. L. (2001). Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7, 345–350. 10.1016/S1471-4914(01)02090-1
147
Sephton S. E. Sapolsky R. M. Kraemer H. C. Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92, 994–1000. 10.1093/jnci/92.12.994
148
Shearman L. P. Jin X. Lee C. Reppert S. M. Weaver D. R. (2000). Targeted disruption of the mPer3 gene: subtle effects on circadian clock function. Mol. Cell. Biol. 20, 6269–6275. 10.1128/MCB.20.17.6269-6275.2000
149
Squires C. E. Escobar G. P. Payne J. F. Leonardi R. A. Goshorn D. K. Sheats N. J. et al . (2005). Altered fibroblast function following myocardial infarction. J. Mol. Cell. Cardiol. 39, 699–707. 10.1016/j.yjmcc.2005.07.008
150
Stanley W. C. (2004). Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther. 9(Suppl. 1), S31–S45. 10.1177/107424840400900104
151
Sun Y. Kiani M. F. Postlethwaite A. E. Weber K. T. (2002). Infarct scar as living tissue. Basic Res. Cardiol. 97, 343–347. 10.1007/s00395-002-0365-8
152
Sun Z. S. Albrecht U. Zhuchenko O. Bailey J. Eichele G. Lee C. C. (1997). RIGUI, a putative mammalian ortholog of the Drosophila period gene. Cell90, 1003–1011. 10.1016/S0092-8674(00)80366-9
153
Suzuki K. Murtuza B. Smolenski R. T. Sammut I. A. Suzuki N. Kaneda Y. et al . (2001). Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation104, I308–I313. 10.1161/hc37t1.094871
154
Takayama T. Wada A. Tsutamoto T. Ohnishi M. Fujii M. Isono T. et al . (2004). Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ. J. 68, 1067–1075. 10.1253/circj.68.1067
155
Taniyama Y. Griendling K. K. (2003). Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension42, 1075–1081. 10.1161/01.HYP.0000100443.09293.4F
156
Thresher R. J. Vitaterna M. H. Miyamoto Y. Kazantsev A. Hsu D. S. Petit C. et al . (1998). Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. Science282, 1490–1494. 10.1126/science.282.5393.1490
157
Tong H. Imahashi K. Steenbergen C. Murphy E. (2002). Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase–dependent pathway is cardioprotective. Circ. Res. 90, 377–379. 10.1161/01.RES.0000012567.95445.55
158
Tsimakouridze E. V. Straume M. Podobed P. S. Chin H. Lamarre J. Johnson R. et al . (2012). Chronomics of pressure overload-induced cardiac hypertrophy in mice reveals altered day/night gene expression and biomarkers of heart disease. Chronobiol. Int. 29, 810–821. 10.3109/07420528.2012.691145
159
Tsinkalovsky O. Rosenlund B. Laerum O. D. Eiken H. G. (2005). Clock gene expression in purified mouse hematopoietic stem cells. Exp. Hematol. 33, 100–107. 10.1016/j.exphem.2004.09.007
160
Tsinkalovsky O. Smaaland R. Rosenlund B. Sothern R. B. Hirt A. Steine S. et al . (2007). Circadian variations in clock gene expression of human bone marrow CD34+ cells. J. Biol. Rhythms22, 140–150. 10.1177/0748730406299078
161
Tsuchiya Y. Minami I. Kadotani H. Nishida E. (2005). Resetting of peripheral circadian clock by prostaglandin E2. EMBO Rep. 6, 256–261. 10.1038/sj.embor.7400356
162
Tsujino T. Naito Y. Kawasaki D. Okuda S. Sakoda T. Fujioka Y. et al . (2005). Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice. Clin. Exp. Hypertens. 27, 159–168. 10.1081/CEH-48744
163
Vanhoutte D. Schellings M. Pinto Y. Heymans S. (2006). Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 69, 604–613. 10.1016/j.cardiores.2005.10.002
164
Vargo J. M. Grachek R. A. Rockswold G. L. (1999). Light deprivation soon after frontal brain trauma accelerates recovery from attentional deficits and promotes functional normalization of basal ganglia. J. Trauma47, 265–272. discussion: 273–264.
165
Vargo J. M. Lai H. V. Marshall J. F. (1998). Light deprivation accelerates recovery from frontal cortical neglect: relation to locomotion and striatal Fos expression. Behav. Neurosci. 112, 387–398. 10.1037/0735-7044.112.2.387
166
Vaughan D. E. (2005). PAI-1 and atherothrombosis. J. Thromb. Haemost. 3, 1879–1883. 10.1111/j.1538-7836.2005.01420.x
167
Virag J. A. Anderson E. J. Kent S. D. Blanton H. D. Johnson T. L. Moukdar F. et al . (2013). Cardioprotection via preserved mitochondrial structure and function in the mPer2-mutant mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 305, H477–H483. 10.1152/ajpheart.00914.2012
168
Virag J. A. Dries J. L. Easton P. R. Friesland A. M. Deantonio J. H. Chintalgattu V. et al . (2010). Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. Am. J. Physiol. Heart Circ. Physiol. 298, H1088–H1095. 10.1152/ajpheart.01280.2008
169
Virag J. I. Murry C. E. (2003). Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am. J. Pathol. 163, 2433–2440. 10.1016/S0002-9440(10)63598-5
170
Viswambharan H. Carvas J. M. Antic V. Marecic A. Jud C. Zaugg C. E. et al . (2007). Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation115, 2188–2195. 10.1161/CIRCULATIONAHA.106.653303
171
Vukolic A. Antic V. Van Vliet B. N. Yang Z. Albrecht U. Montani J. P. (2010). Role of mutation of the circadian clock gene Per2 in cardiovascular circadian rhythms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R627–R634. 10.1152/ajpregu.00404.2009
172
Walters J. F. Hampton S. M. Deanfield J. E. Donald A. E. Skene D. J. Ferns G. A. (2006). Circadian variation in endothelial function is attenuated in postmenopausal women. Maturitas54, 294–303. 10.1016/j.maturitas.2005.12.005
173
Welbourn C. R. Goldman G. Paterson I. S. Valeri C. R. Shepro D. Hechtman H. B. (1991). Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br. J. Surg. 78, 651–655. 10.1002/bjs.1800780607
174
Willich S. N. Kulig M. Muller-Nordhorn J. (2004). European survey on circadian variation of angina pectoris (ESCVA) in treated patients. Herz29, 665–672. 10.1007/s00059-004-2536-x
175
Wong R. Aponte A. M. Steenbergen C. Murphy E. (2010). Cardioprotection leads to novel changes in the mitochondrial proteome. Am. J. Physiol. Heart Circ. Physiol. 298, H75–H91. 10.1152/ajpheart.00515.2009
176
Wu L. Reddy A. B. (2014). Rethinking the clockwork: redox cycles and non-transcriptional control of circadian rhythms. Biochem. Soc. Trans. 42, 1–10. 10.1042/BST20130169
177
Xu Y. Toh K. L. Jones C. R. Shin J. Y. Fu Y. H. Ptacek L. J. (2007). Modeling of a human circadian mutation yields insights into clock regulation by PER2. Cell128, 59–70. 10.1016/j.cell.2006.11.043
178
Yagita K. Yamaguchi S. Tamanini F. Van Der Horst G. T. Hoeijmakers J. H. Yasui A. et al . (2000). Dimerization and nuclear entry of mPER proteins in mammalian cells. Genes Dev. 14, 1353–1363. 10.1101/gad.14.11.1353
179
Yagita K. Yamanaka I. Emoto N. Kawakami K. Shimada S. (2010). Real-time monitoring of circadian clock oscillations in primary cultures of mammalian cells using Tol2 transposon-mediated gene transfer strategy. BMC Biotechnol. 10:3. 10.1186/1472-6750-10-3
180
Yamakawa M. Liu L. X. Date T. Belanger A. J. Vincent K. A. Akita G. Y. et al . (2003). Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. 93, 664–673. 10.1161/01.RES.0000093984.48643.D7
181
Yang X. Wood P. A. Oh E. Y. Du-Quiton J. Ansell C. M. Hrushesky W. J. (2008). Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res. Treat. 117, 423–431. 10.1007/s10549-008-0133-z
182
Young M. E. (2006). The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function. Am. J. Physiol. Heart Circ. Physiol. 290, H1–H16. 10.1152/ajpheart.00582.2005
183
Young M. E. Razeghi P. Cedars A. M. Guthrie P. H. Taegtmeyer H. (2001a). Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ. Res. 89, 1199–1208. 10.1161/hh2401.100741
184
Young M. E. Razeghi P. Taegtmeyer H. (2001b). Clock genes in the heart: characterization and attenuation with hypertrophy. Circ. Res. 88, 1142–1150. 10.1161/hh1101.091190
185
Zhao Z. Q. Vinten-Johansen J. (2006). Postconditioning: reduction of reperfusion-induced injury. Cardiovasc. Res. 70, 200–211. 10.1016/j.cardiores.2006.01.024
186
Zheng B. Larkin D. W. Albrecht U. Sun Z. S. Sage M. Eichele G. et al . (1999). The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature400, 169–173. 10.1038/22659
Summary
Keywords
myocardial infarction, circadian rhythm, acute ischemia, remodeling, cardioprotection
Citation
Virag JAI and Lust RM (2014) Circadian influences on myocardial infarction. Front. Physiol. 5:422. doi: 10.3389/fphys.2014.00422
Received
27 August 2014
Accepted
12 October 2014
Published
30 October 2014
Volume
5 - 2014
Edited by
Ovidiu Constantin Baltatu, University Camilo Castelo Branco, Brazil
Reviewed by
Urs Albrecht, University of Fribourg, Switzerland; Jacqueline Kathleen Phillips, Macquarie University, Australia; Luciana A. Campos, University Camilo Castelo Branco, Brazil
Copyright
© 2014 Virag and Lust.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jitka A. I. Virag, Department of Physiology, Brody School of Medicine, East Carolina University, 600 Moye Blvd., 6N-98, Greenville, NC 27834, USA e-mail: viragj@ecu.edu
This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.